ReP USP - Resultado da busca

Artigo de periodico
Antisense therapy for cardiovascular diseases (2015)
Ian Phillips, M; Costales, Jessica; J. Lee, Robert; Oliveira, E. M.; B. Burns, Andrew
Source: Current Pharmaceutical Design. Unidade: EEFE
Subjects: DOENÇAS CARDIOVASCULARES, SÍNDROME X METABÓLICA, HIPERTENSÃO, HIPERLIPIDEMIA, EXONS, RNA MENSAGEIRO, OLIGONUCLEOTÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
IAN PHILLIPS, M et al. Antisense therapy for cardiovascular diseases. Current Pharmaceutical Design, v. 21, n. 30, p. 4417-4426, 2015Tradução . . Disponível em: https://doi.org/10.2174/1381612821666150803150402. Acesso em: 21 ago. 2024.
APA
Ian Phillips, M., Costales, J., J. Lee, R., Oliveira, E. M., & B. Burns, A. (2015). Antisense therapy for cardiovascular diseases. Current Pharmaceutical Design, 21( 30), 4417-4426. doi:10.2174/1381612821666150803150402
NLM
Ian Phillips M, Costales J, J. Lee R, Oliveira EM, B. Burns A. Antisense therapy for cardiovascular diseases [Internet]. Current Pharmaceutical Design. 2015 ; 21( 30): 4417-4426.[citado 2024 ago. 21 ] Available from: https://doi.org/10.2174/1381612821666150803150402
Vancouver
Ian Phillips M, Costales J, J. Lee R, Oliveira EM, B. Burns A. Antisense therapy for cardiovascular diseases [Internet]. Current Pharmaceutical Design. 2015 ; 21( 30): 4417-4426.[citado 2024 ago. 21 ] Available from: https://doi.org/10.2174/1381612821666150803150402
Artigo de periodico
Optimization of SELEX: comparison of different methods for monitoring the progress of in vitro selection of aptamers (2014)
Mencin, Nina; Smuc, Tina; Vranicar, Marko; Mavri, Jan; Hren, Matjaz; Galesa, Katja; Krkoc, Peter; Ulrich, Henning ; Solar, Borut
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidade: IQ
Subjects: OLIGONUCLEOTÍDEOS, BIOQUÍMICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MENCIN, Nina et al. Optimization of SELEX: comparison of different methods for monitoring the progress of in vitro selection of aptamers. Journal of Pharmaceutical and Biomedical Analysis, v. 91, p. 151-159, 2014Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2013.12.031. Acesso em: 21 ago. 2024.
APA
Mencin, N., Smuc, T., Vranicar, M., Mavri, J., Hren, M., Galesa, K., et al. (2014). Optimization of SELEX: comparison of different methods for monitoring the progress of in vitro selection of aptamers. Journal of Pharmaceutical and Biomedical Analysis, 91, 151-159. doi:10.1016/j.jpba.2013.12.031
NLM
Mencin N, Smuc T, Vranicar M, Mavri J, Hren M, Galesa K, Krkoc P, Ulrich H, Solar B. Optimization of SELEX: comparison of different methods for monitoring the progress of in vitro selection of aptamers [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2014 ; 91 151-159.[citado 2024 ago. 21 ] Available from: https://doi.org/10.1016/j.jpba.2013.12.031
Vancouver
Mencin N, Smuc T, Vranicar M, Mavri J, Hren M, Galesa K, Krkoc P, Ulrich H, Solar B. Optimization of SELEX: comparison of different methods for monitoring the progress of in vitro selection of aptamers [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2014 ; 91 151-159.[citado 2024 ago. 21 ] Available from: https://doi.org/10.1016/j.jpba.2013.12.031
Artigo de periodico
Targeted lipid nanoparticles for antisense oligonucleotide delivery (2014)
Petrilli, Raquel; Eloy, Josimar de Oliveira; Marchetti, Juliana Maldonado; Lopez, Renata Fonseca Vianna; Lee, Robert J.
Source: Current Pharmaceutical Biotechnology. Unidade: FCFRP
Subjects: BIOTECNOLOGIA, FARMACOLOGIA, NANOPARTÍCULAS, OLIGONUCLEOTÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PETRILLI, Raquel et al. Targeted lipid nanoparticles for antisense oligonucleotide delivery. Current Pharmaceutical Biotechnology, v. 15, n. 9, p. 847-855, 2014Tradução . . Disponível em: https://doi.org/10.2174/1389201015666141020155834. Acesso em: 21 ago. 2024.
APA
Petrilli, R., Eloy, J. de O., Marchetti, J. M., Lopez, R. F. V., & Lee, R. J. (2014). Targeted lipid nanoparticles for antisense oligonucleotide delivery. Current Pharmaceutical Biotechnology, 15( 9), 847-855. doi:10.2174/1389201015666141020155834
NLM
Petrilli R, Eloy J de O, Marchetti JM, Lopez RFV, Lee RJ. Targeted lipid nanoparticles for antisense oligonucleotide delivery [Internet]. Current Pharmaceutical Biotechnology. 2014 ; 15( 9): 847-855.[citado 2024 ago. 21 ] Available from: https://doi.org/10.2174/1389201015666141020155834
Vancouver
Petrilli R, Eloy J de O, Marchetti JM, Lopez RFV, Lee RJ. Targeted lipid nanoparticles for antisense oligonucleotide delivery [Internet]. Current Pharmaceutical Biotechnology. 2014 ; 15( 9): 847-855.[citado 2024 ago. 21 ] Available from: https://doi.org/10.2174/1389201015666141020155834
Artigo de periodico
Stable assemblies of cationic bilayer fragments and CpG oligonucleotide with enhanced immunoadjuvant activity in vivo (2012)
Rozenfreld, Julio Henrique Kravcuks; Silva, Sandriana R; Ranéia, Priscila A; Faquim-Mauro, Eliana; Carmona-Ribeiro, Ana Maria
Source: Journal of Controlled Release. Unidade: IQ
Subjects: OLIGONUCLEOTÍDEOS, ADJUVANTES IMUNOLÓGICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROZENFRELD, Julio Henrique Kravcuks et al. Stable assemblies of cationic bilayer fragments and CpG oligonucleotide with enhanced immunoadjuvant activity in vivo. Journal of Controlled Release, v. 160, n. 2, p. 367-373, 2012Tradução . . Disponível em: https://doi.org/10.1016/j.jconrel.2011.10.017. Acesso em: 21 ago. 2024.
APA
Rozenfreld, J. H. K., Silva, S. R., Ranéia, P. A., Faquim-Mauro, E., & Carmona-Ribeiro, A. M. (2012). Stable assemblies of cationic bilayer fragments and CpG oligonucleotide with enhanced immunoadjuvant activity in vivo. Journal of Controlled Release, 160( 2), 367-373. doi:10.1016/j.jconrel.2011.10.017
NLM
Rozenfreld JHK, Silva SR, Ranéia PA, Faquim-Mauro E, Carmona-Ribeiro AM. Stable assemblies of cationic bilayer fragments and CpG oligonucleotide with enhanced immunoadjuvant activity in vivo [Internet]. Journal of Controlled Release. 2012 ; 160( 2): 367-373.[citado 2024 ago. 21 ] Available from: https://doi.org/10.1016/j.jconrel.2011.10.017
Vancouver
Rozenfreld JHK, Silva SR, Ranéia PA, Faquim-Mauro E, Carmona-Ribeiro AM. Stable assemblies of cationic bilayer fragments and CpG oligonucleotide with enhanced immunoadjuvant activity in vivo [Internet]. Journal of Controlled Release. 2012 ; 160( 2): 367-373.[citado 2024 ago. 21 ] Available from: https://doi.org/10.1016/j.jconrel.2011.10.017
Artigo de periodico
Interaction of cationic bilayer fragments with a model oligonucleotide (2011)
Rozenfeld, Julio Henrique Kravcuks; Oliveira, Tiago Ribeiro de ; Lamy, Maria Teresa Moura ; Carmona-Ribeiro, Ana Maria
Source: Biochimica et Biophysica Acta. Unidades: IF, IQ
Subjects: BIOQUÍMICA, OLIGONUCLEOTÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROZENFELD, Julio Henrique Kravcuks et al. Interaction of cationic bilayer fragments with a model oligonucleotide. Biochimica et Biophysica Acta, v. 1808, n. 3, p. 649-655, 2011Tradução . . Disponível em: https://doi.org/10.1016/j.bbamem.2010.11.036. Acesso em: 21 ago. 2024.
APA
Rozenfeld, J. H. K., Oliveira, T. R. de, Lamy, M. T. M., & Carmona-Ribeiro, A. M. (2011). Interaction of cationic bilayer fragments with a model oligonucleotide. Biochimica et Biophysica Acta, 1808( 3), 649-655. doi:10.1016/j.bbamem.2010.11.036
NLM
Rozenfeld JHK, Oliveira TR de, Lamy MTM, Carmona-Ribeiro AM. Interaction of cationic bilayer fragments with a model oligonucleotide [Internet]. Biochimica et Biophysica Acta. 2011 ; 1808( 3): 649-655.[citado 2024 ago. 21 ] Available from: https://doi.org/10.1016/j.bbamem.2010.11.036
Vancouver
Rozenfeld JHK, Oliveira TR de, Lamy MTM, Carmona-Ribeiro AM. Interaction of cationic bilayer fragments with a model oligonucleotide [Internet]. Biochimica et Biophysica Acta. 2011 ; 1808( 3): 649-655.[citado 2024 ago. 21 ] Available from: https://doi.org/10.1016/j.bbamem.2010.11.036
Artigo de periodico
The use of synthetic oligonucleotides as protein inhibitors and anticode drugs in cancer therapy: accomplishments and limitations (2002)
Faria, M.; Ulrich, Henning
Source: Current Cancer Drug Targets. Unidade: IQ
Subjects: OLIGONUCLEOTÍDEOS, PEPTÍDEOS, PROTEÍNAS, BIOQUÍMICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FARIA, M. e ULRICH, Henning. The use of synthetic oligonucleotides as protein inhibitors and anticode drugs in cancer therapy: accomplishments and limitations. Current Cancer Drug Targets, v. 2, n. 4, p. 355-368, 2002Tradução . . Acesso em: 21 ago. 2024.
APA
Faria, M., & Ulrich, H. (2002). The use of synthetic oligonucleotides as protein inhibitors and anticode drugs in cancer therapy: accomplishments and limitations. Current Cancer Drug Targets, 2( 4), 355-368.
NLM
Faria M, Ulrich H. The use of synthetic oligonucleotides as protein inhibitors and anticode drugs in cancer therapy: accomplishments and limitations. Current Cancer Drug Targets. 2002 ; 2( 4): 355-368.[citado 2024 ago. 21 ]
Vancouver
Faria M, Ulrich H. The use of synthetic oligonucleotides as protein inhibitors and anticode drugs in cancer therapy: accomplishments and limitations. Current Cancer Drug Targets. 2002 ; 2( 4): 355-368.[citado 2024 ago. 21 ]

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Subjects

Source title

Indexado em